Silo Pharma receives Notice of Allowance in Japan for SPC-15

Silo Pharma (SILO) announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead asset, SPC-15, a novel intranasal therapeutic targeting Post-Traumatic Stress Disorder, PTSD. The allowed application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” strengthens Silo’s growing intellectual-property portfolio in stress-modulating therapeutics and supports the Company’s strategy to protect its core scientific innovations in key global markets.